ArticlePloS one2025
Risk factors for emergent delivery before 36 weeks among pregnant women with placenta accreta spectrum disorder.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies evaluating risk factors for emergent delivery in women with placenta accreta spectrum disorders have yielded insufficient results. A limited number of studies have evaluated prenatal ultrasound signs of the placenta accreta spectrum as risk factors and have reported inconsistent outcomes. This retrospective study included women with suspected prenatal placenta accreta spectrum who delivered between January 2007 and December 2022 at a tertiary hospital in Southern Thailand. Women who delivered electively or for conditions unrelated to the placenta accreta spectrum before 36 weeks of gestation were excluded. Women who underwent emergent delivery before 36 weeks and delivery after 36 weeks were compared using univariate and multivariable analyses. Overall, 174 women with placenta accreta spectrum were included; 45 (25.0%) underwent emergent delivery before 36 weeks of gestation. Women who delivered before 36 weeks had significantly more premature uterine contractions (41.7% vs. 7.0%, P<0.001), premature rupture of membranes (8.3% vs. 0%, P<0.05), antepartum hemorrhage (75.0% vs. 27.9%, P<0.001), and sonographic findings of placental bulging (45.8% vs. 23.3%, P=0.003) than those who delivered after 36 weeks. The number of premature uterine contractions and antepartum hemorrhage episodes (P<0.001) and more severe placenta accreta spectrum (P=0.003) were significantly associated with emergent delivery. Significant predictors of emergent delivery before 36 weeks were a history of preterm birth (odds ratio: 10.1, 95% confidence interval: 1.0-97.4), presence of premature uterine contractions (9.7, 2.9-31.5), antepartum hemorrhage (6.4, 2.2-18.3), severe placenta accreta spectrum (6.1, 1.5-25.0), and placental bulging (4.4, 1.3-14.2). In conclusion, the significant predictors of emergent delivery before 36 weeks of gestation among women with placenta accreta spectrum were a history of preterm birth, premature uterine contractions or antepartum hemorrhage before 34 weeks, placental bulging, and prenatal diagnosis of severe placenta accreta spectrum.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.